Physician profile
David Rutta
NPI 1811994452
$1,209.00
in general payments reported to CMS, 2019-2025
16 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $139 · 2021: $67.59 · 2022: $256 · 2023: $76.20 · 2024: $85.97 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $330 · Education: $54.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $329.86 |
| Education | $54.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $348.88 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $190.24 | 2019-2025 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $152.47 | 2022 | |
| Janssen Scientific Affairs, LLC | $86.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.33 | 2019-2023 | Entyvio |
| Celgene Corporation | $68.60 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $59.83 | 2022-2025 | Dupixent |
| Pfizer INC. | $50.05 | 2019-2024 | |
| Novo Nordisk INC | $48.28 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $45.45 | 2019 | |
| Daiichi Sankyo INC. | $18.75 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.77 | 2019 | |
| Boston Scientific Corporation | $14.99 | 2021 | |
| Allergan, INC. | $13.81 | 2019 | |
| Alfasigma USA, INC. | $13.18 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rutta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.